Dario Eklund, Santhera CEO
Santhera’s vamorolone bags FDA approval for Duchenne after long journey
Swiss biotech Santhera has at last won FDA approval for its steroidal drug vamorolone to treat boys and men with Duchenne muscular dystrophy, with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.